AB&B Bio-Tech-B (02627.HK) Signs Strategic Cooperation Agreement with Walvax Hong Kong to Globalise Trivalent Influenza Vaccine

Bulletin Express

Yesterday

AB&B Bio-Tech CO., LTD. JS (AB&B Bio-Tech-B, 02627.HK) has entered into a strategic cooperation agreement with Walvax Hong Kong Limited, a wholly-owned subsidiary of Shenzhen-listed Walvax Biotechnology Co., Ltd. (300014.SZ). The agreement, signed on 13 March 2026, focuses on overseas registration, sales and commercialisation of AB&B Bio-Tech’s core product, the trivalent subunit influenza vaccine “Huierkangxin 3”.

Huierkangxin 3, approved for domestic marketing in January 2026, is currently the first and only trivalent subunit influenza vaccine in China indicated for individuals aged six months and above. Leveraging Walvax Hong Kong’s established international distribution channels, the partnership aims to fast-track market penetration across Southeast Asia, Latin America, the Middle East and other Southern Hemisphere regions.

The announcement emphasises that the cooperation framework does not constitute a notifiable or connected transaction under Chapters 14 and 14A of the Hong Kong Listing Rules. A definitive business agreement is still pending; further disclosures will be made in accordance with regulatory requirements. Shareholders and potential investors are advised to exercise caution when trading the company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1129349142"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1129349142\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1129349142?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129349142","market":"us","top_or_hot":-1,"title":"AB&B Bio-Tech-B (02627.HK) Signs Strategic Cooperation Agreement with Walvax Hong Kong to Globalise Trivalent Influenza Vaccine","media":"Bulletin Express","content":"<p>AB&B Bio-Tech CO., LTD. JS (AB&B Bio-Tech-B, 02627.HK) has entered into a strategic cooperation agreement with Walvax Hong Kong Limited, a wholly-owned subsidiary of Shenzhen-listed Walvax Biotechnology Co., Ltd. (300014.SZ). The agreement, signed on 13 March 2026, focuses on overseas registration, sales and commercialisation of AB&B Bio-Tech’s core product, the trivalent subunit influenza vaccine “Huierkangxin 3”.</p>\n<p>Huierkangxin 3, approved for domestic marketing in January 2026, is currently the first and only trivalent subunit influenza vaccine in China indicated for individuals aged six months and above. Leveraging Walvax Hong Kong’s established international distribution channels, the partnership aims to fast-track market penetration across Southeast Asia, Latin America, the Middle East and other Southern Hemisphere regions.</p>\n<p>The announcement emphasises that the cooperation framework does not constitute a notifiable or connected transaction under Chapters 14 and 14A of the Hong Kong Listing Rules. A definitive business agreement is still pending; further disclosures will be made in accordance with regulatory requirements. Shareholders and potential investors are advised to exercise caution when trading the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AB&B Bio-Tech-B (02627.HK) Signs Strategic Cooperation Agreement with Walvax Hong Kong to Globalise Trivalent Influenza Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAB&B Bio-Tech-B (02627.HK) Signs Strategic Cooperation Agreement with Walvax Hong Kong to Globalise Trivalent Influenza Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-13 18:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AB&B Bio-Tech CO., LTD. JS (AB&B Bio-Tech-B, 02627.HK) has entered into a strategic cooperation agreement with Walvax Hong Kong Limited, a wholly-owned subsidiary of Shenzhen-listed Walvax Biotechnology Co., Ltd. (300014.SZ). The agreement, signed on 13 March 2026, focuses on overseas registration, sales and commercialisation of AB&B Bio-Tech’s core product, the trivalent subunit influenza vaccine “Huierkangxin 3”.</p>\n<p>Huierkangxin 3, approved for domestic marketing in January 2026, is currently the first and only trivalent subunit influenza vaccine in China indicated for individuals aged six months and above. Leveraging Walvax Hong Kong’s established international distribution channels, the partnership aims to fast-track market penetration across Southeast Asia, Latin America, the Middle East and other Southern Hemisphere regions.</p>\n<p>The announcement emphasises that the cooperation framework does not constitute a notifiable or connected transaction under Chapters 14 and 14A of the Hong Kong Listing Rules. A definitive business agreement is still pending; further disclosures will be made in accordance with regulatory requirements. Shareholders and potential investors are advised to exercise caution when trading the company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02627","symbol_name":"中慧生物-B","start_time":0,"source_url":"","article_id":"1129349142","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129349142","pubTimestamp":1773396227,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"AB&B Bio-Tech CO., LTD. JS (AB&B Bio-Tech-B, 02627.HK) has entered into a strategic cooperation agreement with Walvax Hong Kong Limited, a wholly-owned subsidiary of Shenzhen-listed Walvax...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02627":"中慧生物-B"},"translate_title":"AB&B Bio-Tech-B(02627.HK)与Walvax Hong Kong签署战略合作协议三价流感疫苗全球化","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02627":1},"content_text":"AB&B Bio-Tech CO., LTD. JS (AB&B Bio-Tech-B, 02627.HK) has entered into a strategic cooperation agreement with Walvax Hong Kong Limited, a wholly-owned subsidiary of Shenzhen-listed Walvax Biotechnology Co., Ltd. (300014.SZ). The agreement, signed on 13 March 2026, focuses on overseas registration, sales and commercialisation of AB&B Bio-Tech’s core product, the trivalent subunit influenza vaccine “Huierkangxin 3”.\nHuierkangxin 3, approved for domestic marketing in January 2026, is currently the first and only trivalent subunit influenza vaccine in China indicated for individuals aged six months and above. Leveraging Walvax Hong Kong’s established international distribution channels, the partnership aims to fast-track market penetration across Southeast Asia, Latin America, the Middle East and other Southern Hemisphere regions.\nThe announcement emphasises that the cooperation framework does not constitute a notifiable or connected transaction under Chapters 14 and 14A of the Hong Kong Listing Rules. A definitive business agreement is still pending; further disclosures will be made in accordance with regulatory requirements. Shareholders and potential investors are advised to exercise caution when trading the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}